NICE recommends first sickle cell disease drug in two decades

5 October 2021

For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the UK's National Health Service (NHS).

Novartis’ (NOVN: VX) Adakveo (crizanlizumab) is recommended by the National Institute for Health and Care Excellence (NICE), which recommends treatments for NHS use in England and Wales, as an option for preventing recurrent sickle cell crises in people aged 16 or over.

More than 300 people a year are expected to receive the treatment via a Managed Access Agreement (MAA), increasing to more than 450 people in subsequent years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK